Notes to the consolidated statements of income

3 Months Ended

Mar. 31, 2018

Notes to the consolidated statements of income

Notes to the consolidated statements of income

2. Notes to the consolidated statements of income

Revenue

The Company has recognized the following revenue in the consolidated statement of income for thethree months ended March 31, 2018:

Revenue
in € THOUS
		For the three months ended March 31, 2018
		Revenue from contracts with customers (IFRS 15)	Other revenue	Total
Health care services		3.155.537	53.258	3.208.795
	Dialysis services	2.648.293	-	2.648.293
	Care Coordination	507.244	53.258	560.502
Health care products		749.098	17.736	766.834
	Dialysis products	729.956	17.736	747.692
	Non-dialysis products	19.142	-	19.142
Total		3.904.635	70.994	3.975.629

Research and development expenses

Research and development expenses of €31.897 for thethree months ended March 31, 2018(for the three monthsended March 31, 2017: €32.136) include expenditure for research and non-capitalizable development costs as well as depreciation and amortization expenses related to capitalized development costs of €80(for the three months ended March 31, 2017: €104).

Earnings per share

The following table contains reconciliations of the numerators and denominators of the basic and fully diluted earnings per share computations for 2018 and 2017:

Reconciliation of Basic and Diluted Earnings per Share
in € THOUS, except share and per share data
	For the three months ended March 31,
	2018		2017
Numerator:
Net income attributable to shareholders of FMC-AG & Co. KGaA		278.555		308.175
Denominators:
Weighted average number of shares outstanding		306.453.070		306.241.321
Potentially dilutive shares		986.454		519.712
Basic earnings per share		0,91		1,01
Fully diluted earnings per share		0,91		1,00